Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.00
Bid: 1,753.00
Ask: 1,754.00
Change: -19.00 (-1.07%)
Spread: 1.00 (0.057%)
Open: 1,770.00
High: 1,770.00
Low: 1,740.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

Fri, 29th Dec 2023 13:01

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

The FTSE 100 index closed up 10.50 points, 0.1%, at 7,733.24. The FTSE 250 ended down 29.53 points, 0.2%, at 19,689.63 and the AIM All-Share closed down 0.34 of a point at 763.32.

The Cboe UK 100 ended up 0.2% at 772.47, the Cboe UK 250 closed down 0.1% at 17,163.49, and the Cboe Small Companies ended up 0.7% at 14,992.05.

At the time of the early London market close, the CAC 40 in Paris was up 0.4%, while the DAX 40 in Frankfurt was up 0.3%, on track to add 15% and 19% respectively this year.

"The UK stock market has, once again, frustrated those who were convinced it was cheap and lived down the expectations of those who asserted it was cheap for good reason," said AJ Bell investment director AJ Bell commented last week.

In comparison to the double-digit returns offered elsewhere, the FTSE 100 offered a paltry 2.4% in 2023.

"However, that gain is supplemented by a dividend yield north of 3.5%, share buybacks and also mergers and acquisitions, so the total cash return will still be in the low double-digit percentage range. That beats inflation, government bond yields and returns on cash. The takeover activity witnessed in the UK again hints that there is value to be found, especially as many deals have been done at a big premium, and as we enter 2024 the UK market may still feature stocks that could appeal to a wide range of investor requirements and risk appetites."

Standout annual performances in the FTSE 100 came from Rolls-Royce, with the jet engine maker's shares tripling in value under the stewardship of its new chief executive Tufan Erginbilhic. Recent returnee to the large-cap index, Marks & Spencer, doubled the value of its shares amid robust trading despite a fairly downbeat consumer environment.

Dragging on the index were miners Anglo American and Fresnillo, losing 40% and 34% respectively. They faced headwinds from falling commodity prices amid a more downbeat assessment for China's economy, the country being a key importer of commodities.

Among its noteworthy stocks for 2024, AJ Bell points to GSK, with its shares closing the year flat, and Legal & General, which fell 0.1% this year.

Pharmaceutical firm GSK said the firm's relatively "static" share price over 2023, leads to a "tempting valuation".

"The relatively predictable demand, high margins and consistent cashflow that can result from a successful drug development model can also appeal at times of economic uncertainty, so GSK may appeal to those investors who fear that an unexpected recession could creep up on the UK equity market next year," AJB's Mould explained.

Meanwhile, life insurance, pensions and investment firm L&G might have its time in the sun, as borrowing costs wind down.

"The lowly valuation on an earnings basis, and forecast 8.5% dividend yield for 2024, offer the potential for capital appreciation and income generation, and management has a plan to increase its shareholder distribution by some 5% a year. Moreover, the balance sheet is strong," Mould noted.

The more domestically-focused FTSE 250 index, adding 2.9% in 2023, proved more resilient than many had expected amid the cost-of-living crisis and stagnant UK economic growth. It shed over 20% in 2022. Meanwhile, the AIM All-Share fell 9.0%, after plunging 31% in 2022.

On the UK front, there is expected to be a general election at some point in 2024. In the meantime, eyes will be on the March budget from Chancellor Jeremy Hunt, with analysts forecasting inheritance tax reform, cuts to fuel duty and income tax, and help for first-time home buyers.

All the while, the UK economy teeters on the edge of recession, as the latest official figures revealed 0.1% quarterly contraction for the third quarter. On a brighter note, inflation cooled more quickly than expected, dropping to 3.9% in November. Still, this remains well above the Bank of England's target of 2%, with Trading Economics forecasts indicating it will only cool to 3.0% by the third quarter of 2024.

The pound finishes the year on a much stronger footing, trading at USD1.2747, slightly higher than USD1.2741 at the London equities close on Thursday.

This is quite a jump from USD1.2054 at the end of 2022, and partly due to the more hawkish positioning of the BoE in comparison to the relatively dovish Fed.

The BoE is expected to begin a slow process of rate cuts from May, at the earliest. Following the Fed's December decision to keep rates on pause, the market rushed to price in at least 150 basis points of interest rate cuts in 2024 beginning from March. This has put selling pressure on the dollar in recent weeks.

The euro traded at USD1.1074, fading slightly from USD1.1078 – but firm on USD1.0686 at the end of 2022. Against the yen, the dollar was quoted at JPY141.42, up versus JPY141.08 – making strong annual gains on JPY131.84, as the Bank of Japan kept its ultra-loose monetary policy in place.

However, market expectations for the path of rates are markedly more dovish than those of the Fed itself. The central bank's latest quarterly dot plot showed that most officials expect rates to be in the range of 4.4% to 4.9% by the end of 2024. The federal funds rate currently stands at a 22-year high of 5.25% to 5.5%, so the dot plot is showing cuts of 100 basis points or less.

On Friday, the Dow Jones Industrial Average, the S&P 500, and the Nasdaq Composite were all called flat.

The Dow is up 14% so far in 2023, the S&P 500 up 25%, and the tech-heavy Nasdaq Composite is up 45%.

"The million-dollar question is what will happen next year. Of course, we don't know, nobody knows, and our crystal balls completely missed the AI rally that marked 2023, yet the general expectation is a cool down in the technology rally, and a rebalancing between the big tech stocks and the S&P493 on narrowing profit lead for the Magnificent 7 compared to the rest of the index in 2024," said Swissquote Bank senior analyst Ipek Ozkardeskaya.

The magnificent seven refers to Microsoft, Apple, Amazon, Meta, Google, Tesla and Nvidia – tech shares which generated almost all of the returns for the S&P 500 and Nasdaq 100.

Nvidia stole the show in 2023, amid the explosion of interest in artificial intelligence. Its shares leapt from USD147 at the beginning of the year to USD495 by the end.

Meanwhile, in commodities, oil prices have operated in a comparatively more stable range this year, after the volatility of 2022 amid the energy crisis prompted by Russia's invasion of Ukraine.

Brent oil was trading at USD77.56 a barrel early Friday, higher than USD78.70 late Thursday. Brent ended 2022 in London at USD83.21, so lost 6.8% over the course of 2023 – its first annual loss since 2020.

Fears of rising oil prices stemming from the conflict in the Middle East have failed to come to pass so far. Further, the waning efficacy of Opec+ alliance production cuts, mounting inventories, and a muted demand outlook continue to weigh on the outlook for oil. London's BP and Shell, which notched gains of 35% and 37% respectively last year, saw a more moderate performance. BP fell 3.7%, while Shell rose 8.6%.

Unlike the oil market, gold had a stellar 2023.

Spot gold has advanced 14% this year. It soared to an all-time record high of USD2,075 an ounce early this month. The precious metal has regained its lustre amid rising hopes that the Fed could pivot to monetary policy easing, and as it benefitted from its safe-haven status, thanks to geopolitical risks.

Dutch bank ING believes that safe-haven demand and the US interest rate outlook will keep gold supported in 2024, expecting the price to remain above the USD2,000 level next year. They even predict a new record high in 2024.

In next week's economic calendar, major financial markets, including the UK, US and Tokyo will remain closed on Monday to mark New Year's Day.

Tuesday brings the latest series of manufacturing PMIs, with services PMIs to follow on Thursday. On Wednesday there will be the US JOLTS and ADP jobs reports and the Federal Reserve's meeting minutes, followed by the closely-watched non-farm payrolls print on Friday.

In the UK corporate calendar, there will be a much-anticipated trading statement from Next on Thursday, which will set the bar for the UK retail sector's festive performance.

By Elizabeth Winter, Alliance News deputy news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more
20 Feb 2024 08:55

IN BRIEF: Diageo welcomes GSK's CFO as non-executive director

Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."

Read more
15 Feb 2024 14:44

UK dividends calendar - next 7 days

Friday 16 February 
JPMorgan Asia Growth & Income PLCdividend payment date
JPMorgan Japan Small Cap Growth & Income PLCdividend payment date
Murray International Trust PLCdividend payment date
Premier Miton Group PLCdividend payment date
Schroder Oriental Income Funddividend payment date
Solid State PLCdividend payment date
Monday 19 February 
no events scheduled 
Tuesday 20 February 
Invesco Bond Income Plus Ltd 
Wednesday 21 February 
no events scheduled 
Thursday 22 February 
abrdn Asia Focus PLCex-dividend payment date
Alumasc Group PLCex-dividend payment date
AstraZeneca PLCex-dividend payment date
BlackRock Throgmorton Trust PLCex-dividend payment date
Braemar PLCex-dividend payment date
easyJet PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
Endeavour Mining PLCex-dividend payment date
FRP Advisory Group PLCex-dividend payment date
Gateley Holdings PLCex-dividend payment date
GSK PLCex-dividend payment date
Hercules Site Services PLCex-dividend payment date
Jersey Electricity PLCex-dividend payment date
Land Securities Group PLCex-dividend payment date
Molten Ventures VCT PLCex-dividend payment date
Northern Bear PLCex-dividend payment date
Redrow PLCex-dividend payment date
Samuel Heath & Sons PLCex-dividend payment date
Titon Holdings PLCex-dividend payment date
Unilever PLCex-dividend payment date
Van Elle Holdings PLCex-dividend payment date
Virgin Money UK PLCex-dividend payment date
Witan Investment Trust PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
15 Feb 2024 11:02

Berenberg hikes target price on GSK

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.

Read more
15 Feb 2024 09:45

LONDON BROKER RATINGS: Jefferies cuts Kingfisher but Citi raises

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
15 Feb 2024 08:49

GSK completes USD1.4 billion purchase of respiratory firm Aiolos Bio

(Alliance News) - GSK PLC on Thursday said it has completed the acquisition of Aiolos Bio Ltd, expanding its respiratory portfolio with a potential "best-in-class" asthma treatment.

Read more
13 Feb 2024 16:53

LONDON MARKET CLOSE: Stocks in red amid sticky US inflation data

(Alliance News) - Stock prices in London closed in the red on Tuesday, after a key US inflation reading came in hotter-than-expected.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.